BSc (Hons) (Bath), PhD (Bath)

Mark is UniQuest’s executive director, intellectual property commercialisation. He leads a team responsible for commercialising UQ’s intellectual property.

Mark completed his undergraduate studies in chemistry, postgraduate studies in medicinal chemistry sponsored by the pharma company Organon (now Merck), and postdoctoral studies in the discovery of novel calcium channel antagonists in the UK.

Mark was previously senior director, commercial engagement – health, and before that manager of innovation and commercial development for IMB. Before joining UniQuest, he held positions as executive vice-president (business development) of the European-based biotech company Evotec, and president of the drug discovery operations division of Evotec, responsible for some 200 scientists.

Mark currently serves as a director of the Australian biotech company, Vaxxas Pty Ltd and was previously a board director of Dimerix Bioscience Pty Ltd and a board observer of Spinifex Inc.